These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16759550)

  • 1. [Smoking cessation after 12 months follow-up at a smoking cessation unit].
    Pascual-Lledó JF; De la Cruz-Amorós E; Bustamante-Navarro R; Buades-Sánchez MR; Contreras-Santos C; Castillo-Aguilar C
    Med Clin (Barc); 2006 Apr; 126(16):601-6. PubMed ID: 16759550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smoking cessation treatment among dually diagnosed individuals: preliminary evaluation of different pharmacotherapies.
    Saxon AJ; Baer JS; Davis TM; Sloan KL; Malte CA; Fitzgibbons K; Kivlahan DR
    Nicotine Tob Res; 2003 Aug; 5(4):589-96. PubMed ID: 12959797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors in smoking cessation with combined therapy with bupropion and nicotine patches.
    Sampablo I; Lores L; Coll-Klein F; Jimenez C; Rebasa P
    Monaldi Arch Chest Dis; 2003; 59(2):171-6. PubMed ID: 14635510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of pharmacological tobacco cessation relapse rates.
    McMurry TB
    J Community Health Nurs; 2006; 23(1):15-28. PubMed ID: 16445361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review and meta-analysis of combination therapy for smoking cessation.
    Shah SD; Wilken LA; Winkler SR; Lin SJ
    J Am Pharm Assoc (2003); 2008; 48(5):659-65. PubMed ID: 18826906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.
    Evins AE; Cather C; Culhane MA; Birnbaum A; Horowitz J; Hsieh E; Freudenreich O; Henderson DC; Schoenfeld DA; Rigotti NA; Goff DC
    J Clin Psychopharmacol; 2007 Aug; 27(4):380-6. PubMed ID: 17632223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of bupropion in the management of smoking cessation.
    Jorenby D
    Drugs; 2002; 62 Suppl 2():25-35. PubMed ID: 12109933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smoker characteristics and smoking-cessation milestones.
    Japuntich SJ; Leventhal AM; Piper ME; Bolt DM; Roberts LJ; Fiore MC; Baker TB
    Am J Prev Med; 2011 Mar; 40(3):286-94. PubMed ID: 21335259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological approaches to smoking cessation.
    Mitrouska I; Bouloukaki I; Siafakas NM
    Pulm Pharmacol Ther; 2007; 20(3):220-32. PubMed ID: 16497526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparing the effectiveness of different treatment modalities on the smoking cessation rates].
    Onen ZP; Sen E; Eriş Gülbay B; Oztürk A; Akkoca Yıldız O; Acıcan T; Saryal S; Karabıyıkoğlu G
    Tuberk Toraks; 2010; 58(4):385-92. PubMed ID: 21341115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting.
    Silva AP; Scholz J; Abe TO; Pinheiro GG; Gaya PV; Pereira AC; Santos PC
    BMC Cardiovasc Disord; 2016 Jan; 16():2. PubMed ID: 26728720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
    JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Success of smoking cessation interventions during pregnancy.
    Bérard A; Zhao JP; Sheehy O
    Am J Obstet Gynecol; 2016 Nov; 215(5):611.e1-611.e8. PubMed ID: 27402053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention.
    Croghan IT; Hurt RD; Dakhil SR; Croghan GA; Sloan JA; Novotny PJ; Rowland KM; Bernath A; Loots ML; Le-Lindqwister NA; Tschetter LK; Garneau SC; Flynn KA; Ebbert LP; Wender DB; Loprinzi CL
    Mayo Clin Proc; 2007 Feb; 82(2):186-95. PubMed ID: 17290726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of the nicotine patch and gum for the treatment of adolescent tobacco addiction.
    Moolchan ET; Robinson ML; Ernst M; Cadet JL; Pickworth WB; Heishman SJ; Schroeder JR
    Pediatrics; 2005 Apr; 115(4):e407-14. PubMed ID: 15805342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.
    Aubin HJ; Lebargy F; Berlin I; Bidaut-Mazel C; Chemali-Hudry J; Lagrue G
    Addiction; 2004 Sep; 99(9):1206-18. PubMed ID: 15317642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking.
    Hurt RD; Krook JE; Croghan IT; Loprinzi CL; Sloan JA; Novotny PJ; Kardinal CG; Knost JA; Tirona MT; Addo F; Morton RF; Michalak JC; Schaefer PL; Porter PA; Stella PJ
    J Clin Oncol; 2003 Mar; 21(5):914-20. PubMed ID: 12610193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised trial of glucose tablets to aid smoking cessation.
    West R; May S; McEwen A; McRobbie H; Hajek P; Vangeli E
    Psychopharmacology (Berl); 2010 Jan; 207(4):631-5. PubMed ID: 19859699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.
    Lerman C; Jepson C; Wileyto EP; Epstein LH; Rukstalis M; Patterson F; Kaufmann V; Restine S; Hawk L; Niaura R; Berrettini W
    Neuropsychopharmacology; 2006 Jan; 31(1):231-42. PubMed ID: 16123753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.